Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Overview

To assess the efficacy of triptorelin pamoate prolonged release (PR) 3-month formulation in Chinese female subjects with endometriosis by demonstrating the non-inferiority of triptorelin pamoate PR 3-month formulation injected once as compared to triptorelin acetate PR 1-month formulation injected 3 times consecutively.

Full Title of Study: “A Phase III, Multicentre, Randomised, Open-label, Parallel, Active-controlled Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: May 17, 2019

Interventions

  • Drug: Triptorelin Pamoate PR 3-month
    • 15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
  • Drug: Triptorelin Acetate PR 1-month
    • 3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)

Arms, Groups and Cohorts

  • Experimental: Triptorelin pamoate PR 3-month
    • Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
  • Active Comparator: Triptorelin acetate PR 1-month
    • Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Week 12
    • Time Frame: Week 12
    • Castration was defined as serum oestradiol (E2) ≤184 picomoles/litre (pmol/L) or 50 picograms/millilitre (pg/mL). The primary endpoint was evaluated based on centralised blinded bioanalysis of serum samples for E2. The percentage of subjects castrated and the 95% asymptotic confidence intervals (CIs), calculated from binomial distribution, are presented.

Secondary Measures

  • Percentage of Subjects Castrated (E2 ≤184 Pmol/L or 50 pg/mL) at Weeks 4 and 8
    • Time Frame: Weeks 4 and 8
    • The percentages of subjects who were castrated at Weeks 4 and 8 where castration was defined as serum E2 ≤184 pmol/L or 50 pg/mL are presented. The 95% asymptotic CIs were calculated from the binomial distribution.
  • Percentage of Subjects Castrated (E2 ≤110 Pmol/L or 30 pg/mL) at Weeks 4, 8 and 12
    • Time Frame: Weeks 4, 8 and 12
    • The percentages of subjects who were castrated at Weeks 4, 8 and 12 where castration was defined as serum E2 ≤110 pmol/L or 30 pg/mL are presented. The 95% asymptotic CIs were calculated from the binomial distribution.
  • Change From Baseline in Endometriosis-associated Pelvic Pain at Weeks 4, 8 and 12
    • Time Frame: Baseline (Day 1) and Weeks 4, 8 and 12
    • Endometriosis-associated pelvic pain was assessed using a 100 millimetres (mm) visual analogue scale (VAS) where subjects indicated the subjective level of their most severe endometriosis pain over the last 4 weeks by making a single vertical mark on the line ranging from ‘absence of pain’ (0 mm) to ‘unbearable pain’ (100 mm). Lower scores indicated a better outcome. Baseline was defined as the last available assessment prior to the first dose of study medication. The least squares (LS) mean change from baseline at each timepoint as measured by the VAS is presented.
  • Mean E2 Concentration at Weeks Baseline and 4, 8 and 12
    • Time Frame: Baseline (Day 1) and Weeks 4, 8 and 12
    • The mean serum E2 concentrations at baseline and Weeks 4, 8 and 12 are presented.
  • Mean Follicle Stimulating Hormone (FSH) Concentration at Baseline and Weeks 4, 8 and 12
    • Time Frame: Baseline (Day 1) and Weeks 4, 8 and 12
    • The mean FSH concentrations at baseline and Weeks 4, 8 and 12 are presented.
  • Mean Luteinising Hormone (LH) Concentration at Baseline and Weeks 4, 8 and 12
    • Time Frame: Baseline and Weeks 4, 8 and 12
    • The mean LH concentrations at baseline and Weeks 4, 8 and 12 are presented.
  • Median Time to Menses Recovery
    • Time Frame: Baseline (Day 1) up to Week 40 (end of study visit)
    • Time to menses recovery was defined as the time (in days) between the date of the last dose of study medication and the date of the first day the subject observed menstrual bleeding of the next menstrual period. Menses recovery status was assessed at all study visits from Day 1 to the end of study visit. The median time to menses recovery was analysed using the Kaplan-Meier method.

Participating in This Clinical Trial

Inclusion Criteria

  • Female subjects aged from 18 to 45 years inclusive at the date of informed consent. – A history of active and regular menstrual cycles of 21 to 35 days (inclusive) in the 6 months prior to the screening visit. – A diagnosis of endometriosis, confirmed by laparoscopy or laparotomy within10 years prior to the screening visit. – Requires treatment with a Gonadotrophin releasing hormone (GnRH) agonist for a period of 6 months in the judgement of the investigator. Exclusion Criteria:

  • A current history of undiagnosed abnormal genital bleeding. – Received treatment with a GnRH agonist within 6 months prior to the screening visit. – Received any other hormonal treatment within 3 months prior to the screening visit (oestrogens, progestogens, danazol, gestrinone and cyproterone acetate etc). – Chronic pelvic pain that is not caused by endometriosis, that would interfere with the assessment of endometriosis-associated pelvic pain.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ipsen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ipsen Medical Director, Study Director, Ipsen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.